COST-UTILITY OF GRANULOCYTE-COLONY STIMULATING FACTORS (G-CSFS) FOR PRIMARY PROPHYLAXIS (PP) OF CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA (FN) IN BREAST CANCER PATIENTS IN THE NETHERLANDS

被引：0
|
作者：
Somers, L. [1 ]
Timmer-Bonte, J. N. H. [2 ]
Gelderblom, H. [3 ]
机构：
[1] OncoLogX Bvba, Wuustwezel, Belgium
[2] Alexander Monro Breast Canc Hosp, Bilthoven, Netherlands
[3] Leiden Univ, Med Ctr, Leiden, Netherlands
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.531
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A415 / A415
页数：1
相关论文
共 50 条
  • [1] COST-UTILITY OF GRANULOCYTE-COLONY STIMULATING FACTORS FOR PRIMARY PROPHYLAXIS OF CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA IN BREAST CANCER PATIENTS IN BELGIUM
    Somers, L.
    Malfait, M.
    Danel, A.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A427 - A427
  • [2] Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer
    Matti S. Aapro
    Stephen Chaplin
    Paul Cornes
    Sebastian Howe
    Hartmut Link
    Natalia Koptelova
    Andrea Mehl
    Mario Di Palma
    Bridgette Kanz Schroader
    Robert Terkola
    [J]. Supportive Care in Cancer, 2023, 31
  • [3] Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer
    Aapro, Matti S.
    Chaplin, Stephen
    Cornes, Paul
    Howe, Sebastian
    Link, Hartmut
    Koptelova, Natalia
    Mehl, Andrea
    Di Palma, Mario
    Schroader, Bridgette Kanz
    Terkola, Robert
    [J]. SUPPORTIVE CARE IN CANCER, 2023, 31 (10)
  • [4] COST-EFFECTIVENESS OF GRANULOCYTE COLONY STIMULATING FACTORS (G-CSFS) FOR THE PREVENTION OF FEBRILE NEUTROPENIA IN BREAST CANCER PATIENTS
    Koptelova, N.
    Mehl, A.
    Chaplin, S.
    Maiese, B. A.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S85 - S85
  • [5] COST-EFFECTIVENESS AND COST-UTILITY OF GRANULOCYTE COLONY-STIMULATING FACTORS IN THE PRIMARY PROPHYLAXIS OF CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA (FN) IN BREAST CANCER PATIENTS IN GREECE: A COMPARATIVE ANALYSIS
    Kourlaba, G.
    Palaka, E.
    Papagiannopoulou, V
    Maniadakis, N.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A633 - A633
  • [6] NUMBER NEEDED TO TREAT AND COST UTILITY ANALYSIS OF GRANULOCYTE-COLONY STIMULATING FACTORS FOR PRIMARY PROPHYLAXIS OF CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA IN DLBCL PATIENTS IN THE NETHERLANDS
    Lugtenburg, E.
    Levin, M. D.
    Somers, L.
    [J]. HAEMATOLOGICA, 2014, 99 : 698 - 699
  • [7] Febrile neutropenia primary prophylaxis with granulocyte-colony stimulating factors (G-CSF) in breast cancer
    Younis, T.
    Rayson, D.
    Skedgel, C.
    [J]. CANCER RESEARCH, 2013, 73
  • [8] Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
    Chris Skedgel
    Daniel Rayson
    Tallal Younis
    [J]. Supportive Care in Cancer, 2016, 24 : 387 - 394
  • [9] Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
    Skedgel, Chris
    Rayson, Daniel
    Younis, Tallal
    [J]. SUPPORTIVE CARE IN CANCER, 2016, 24 (01) : 387 - 394
  • [10] A Comparison of Brand and Biosimilar Granulocyte-Colony Stimulating Factors for Prophylaxis of Chemotherapy-Induced Febrile Neutropenia
    Douglas, Andrea G.
    Schwab, Phil
    Lane, Daniel
    Kennedy, Kenneth
    Slabaugh, S. Lane
    Bowe, Andy
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (12): : 1221 - 1226
12345